Previous studies performed in this laboratory have demonstrated somatostatin-containing cells in close proximity to gastrin cells in antral mucosa and have shown that somatostatin exerts a local regulatory effect on gastrin release. The present studies were directed to determine whether the effects of somatostatin on the antral gastrin cell involve pretranslational events. The effects of somatostatin on gastrin mRNA were determined by dot blot hybridization using a gastrin antisense RNA probe derived from human gastrin cDNA. Inclusion of somatostatin in the incubation medium caused a dosedependent inhibition of steady-state gastrin mRNA. Conversely, when antral somatostatin was neutralized by the addition of specific somatostatin antibodies to the incubation medium, gastrin mRNA levels increased by 116±31% over control values (P < 0.01). Northern blot hybridization of total antral RNA demonstrated a single major band with a molecular size of -620 nucleotides, closely matching the predicted size of gastrin mRNA. The effect of somatostatin on the rate of gastrin gene transcription was examined using nuclear run-off transcription assays. Inclusion of antibodies to somatostatin in the incubation medium resulted in a 33.8±3.3% increase in gastrin gene transcriptional activity (P < 0.01). These studies indicate that, in addition to its established effect on peptide release, somatostatin exerts inhibitory effects on antral gastrin cells at the pretranslational level. Although this inhibition appears to occur in part at the gene transcriptional level, the results also indicate that somatostatin may affect posttranscriptional processing of gastrin mRNA.
Introduction
Although originally identified as an inhibitor of growth hormone release (1), somatostatin is a potent inhibitor of several gastrointestinal regulatory peptides, such as gastrin (2, 3) . In addition to its localization in several digestive organs, including the stomach, intestine, biliary tree, and pancreas (4, 5), somatostatin-like immunoreactivity has been demonstrated in the retina (6) in close proximity to both a-and /3-islet cells (7) , in the cardiac vagus (8) , and in the glomerulus of the kidney (9) . It has been suggested that circulating somatostatin may play a physiologic role in the stomach (10, 11) and pancreas (12) . However, due to its widespread distribution somatostatin is a likely candidate for a local paracrine role in the regulation of various endocrine and exocrine cells (13) . Recent studies performed in this (14) and other laboratories (15, 16) have supported the hypothesis that antral somatostatin exerts inhibitory effects on gastrin release through paracrine pathways, accomplished by release of the peptide from somatostatincontaining D cells into the immediate interstitial environment of the gastrin cell. Using rat antral mucosa in short-term tissue culture, immunoneutralization of endogenous somatostatin with specific antisera resulted in increased medium gastrin concentrations, suggesting that somatostatin exerts a continuous inhibitory effect on the gastrin cell (14) .
These studies, as well as those by Harty et al. (17) , have demonstrated that somatostatin inhibition of gastrin release involves posttranslational events. However, the precise mechanisms by which somatostatin inhibits the gastrin cell have not been clearly and thoroughly defined. The purpose of the present study was to determine whether the local regulatory effects of somatostatin on antral gastrin cells also involve pretranslational events, and specifically whether gastrin gene transcriptional activity may be affected. Our results indicate that somatostatin decreases levels of gastrin mRNA and partially inhibits gastrin gene transcription in dog antral mucosa.
Methods
Preparation and incubation ofdog antral mucosa. Antral mucosa was obtained from fasting mongrel dogs that were anesthetized with achloralose (Sigma Chemical Co., St. Louis, MO). The dogs were being used as heart donors, and antrectomy was performed immediately after removal ofthe heart. Antrums were then thoroughly washed with modified (calcium free) Krebs-Henseleit bicarbonate buffer (KHB)' (pH 7.4; 110 mM NaCi, 4.7 mM KCl, 1.13 mM MgC12, 1.15 mM NaH2PO4, 25 mM NaHCO3, 10 mM Hepes, 5.6 mM glucose, 100 U/ml penicillin, and 100 mg/ml streptomycin; all reagents obtained from Fisher Scientific Co., Pittsburgh, PA). Antral mucosa stripped from the muscularis was sectioned into 250 X 1,000-,u fragments with a McIlwain tissue chopper (Brinkmann Instruments, Inc., Westbury, NY). Antral mucosal tissue fragments were stabilized during an initial 45-min period in KHB at 37°C and gassed with 95% 02-5% CO2-Stabilization and test cultures were performed in a Dubnoff metabolic shaking incubator (GCA/Precision Scientific Group, Chicago, IL) at 100 oscillations/min as described previously (14, 18) . Mucosal fragments were separated from stabilization medium by centrifugation at 400 g for 5 min and then resuspended in either control or test media in 50-ml polypropylene culture flasks.
Antral mucosal strips were incubated under control conditions in KHB containing normal rabbit serum at a final dilution of 1:500. The control rabbit serum was obtained from two healthy fasting New Zealand White rabbits immunized with BSA. The effect of somatostatin on gastrin mRNA levels was examined by immunoneutralization with the addition of specific rabbit somatostatin antibodies to the incubation medium. Somatostatin antiserum 117-3 (generously provided by Dr. J. E. McGuigan, Gainesville, FL) has been fully characterized elsewhere (18) and was used in these experiments at a final dilution of 1:500. The effect of somatostatin on antral gastrin mRNA levels was also tested by inclusion of varying concentrations of cyclic tetradecapeptide somatostatin (15-28) or the analogue [Leu8,p-Trp22,Tyr28]-somatostatin 28 (both purchased from Peninsula Laboratories, Inc., Belmont, CA) in the incubation medium. This analogue, although biologically active, is nonimmunoreactive with somatostatin antiserum 117-3. After a 60-min incubation antral mucosal fragments were removed for either total RNA extraction or nuclear isolation, followed by dot blot or Northern blot hybridization.
RNA extraction. RNA was extracted from antral mucosa using a modification of the method of Chirgwin et al. (19, 20) . Briefly, the antral tissue was homogenized in 4 M guanidinium isothiocyanate, 25 mM sodium citrate, 100 mM 2-mercaptoethanol, 0.5% sodium Nlauroylsarcosine. Cesium chloride was added to the homogenate at a ratio of 1 g/2.5 ml. The homogenate was then loaded onto a cushion of 5.7 M cesium chloride and centrifuged for 18 h at 121,000 g. The resulting RNA pellet was extracted twice with chloroform:n-butanol (4:1). RNA in the aqueous phase was precipitated in ethanol and RNA yields were examined by absorption at 260 and 280 nm. A260:A280 ratios of 1.95-2.0 indicated that the samples were essentially free of contaminating protein. Qualitative analysis of total RNA was also determined in every experiment by gel electrophoresis. RNA samples were denatured as described below and subjected to electrophoresis through 1.4% agarose in the presence of formaldehyde. Quantification of total RNA was performed by dissolving samples in distilled water and determining absorption at 260 nm (OD260 of 1 = 40 Mg RNA/ml).
Isolation ofnuclei and nuclear run-offassays. Nuclei were isolated from antral mucosa incubated in the presence or absence ofantibodies to somatostatin using a modified method of Mulvihill et al. (21) . The antral mucosal strips were homogenized in 0.32 M sucrose, 3 mM calcium chloride, 2 mM magnesium acetate, 0.1 mM EDTA, 1O mM Tris-HCI (pH 8.0), 0.1% Triton X-O00, and 1 mM DTT, using 15 strokes of the tight pestle of a Stir-R tissue homogenizer (Tri-R Instruments, Inc., Rockville Centre, NY) (21). The homogenate was diluted with 2 vol of a 2-M sucrose buffer consisting of 2 M sucrose, 5 mM magnesium acetate, 0.1 mM EDTA, 1O mM Tris-HCl (pH 8.0), and 1 mM DTT, then layered over a lO-ml cushion ofthe 2-M sucrose buffer and centrifuged at 30,000 g for 45 min at 4°C. The nuclear pellet was suspended in 100-150 Ml of 25% glycerol, 5 mM magnesium acetate, 0.1 mM EDTA, 50 mM Tris-HCl (pH 8.0) and 5 mM DTT (22) . For the nuclear transcriptional assay isolated nuclei (70 ul) were incubated with ATP, CTP, and UTP (2 mM each), 0.2 mM GTP, a-32P-GTP (200 MCi) in 0.15 M potassium chloride, and 3 mM magnesium acetate. The reaction (200 ,l) was continued for 45 min at 25°C (23, 24) . For the detection of specific transcripts, 5-10 g of plasmid pHG529 (a generous gift from Dr. J. Rehfeld, Copenhagen, Denmark) containing gastrin cDNA was hybridized to the run-off products for 24-36 h. Chicken cytoskeletal actin cDNA (donated by Dr. D. Tenen, Boston, MA), ubiquitin cDNA (kindly provided by Dr. K. Lund, Chapel Hill, NC), and plasmids pgemTm 3 and pBR322 were used as controls. Dot blot and Northern blot hybridizations. Preliminary experiments indicated that the level of sensitivity obtained using conventional nick-translated cDNA hybridization probes was insufficient to permit detection of gastrin mRNA from the dog antrum. Therefore, antisense gastrin RNA probes were generated that permitted detection of < 5 pg of gastrin mRNA. A 463-bp cDNA fragment encoding human gastrin (25) was cloned into the expression vector pgemTm-blue (Riboprobe; Promega Biotec, Madison, WI) using standard techniques (26) . Labeled antisense gastrin RNA probes were prepared by cleaving with Sal I and transcribing with SP6 polymerase in the presence of a-32P-CTP as described by Melton et al. (27) . Northern and dot blot hybridizations were performed using relatively stringent conditions (450C, 50% formamide, 5 X sodium saline citrate, SSC) in order to eliminate nonspecific hybridization to ribosomal RNA.
For dot blot analysis ofgastrin mRNA, total antral RNA was denatured in 50% deionized formamide, 6% formaldehyde at 60'C for 15 min and then spotted on Gene Screen Plus filters (New England Nuclear, Boston, MA). The plasmid pHG529 (25) containing gastrin cDNA was used as a positive control and ribosomal RNA served as a negative control. Chicken cytoskeletal actin cDNA and ubiquitin cDNA were used as controls for genomic specificity. The blots were prehybridized for 2 h at 450C in 5X SSC (1X SSC = 0.15 M NaCl, 0.015 M Na citrate), SX Denhardt's (IX = 0.02% polyvinylpyrrolidone, Ficoll, and BSA, 50% formamide, and 250 Mg/ml salmon sperm DNA. They were then hybridized overnight under the same conditions with -3X 106 cpm/ml of the antisense gastrin RNA probe. The blots were washed twice at room temperature in 2X SSC, followed by two washes in 2X SSC, 0.1% SDS at 60°C. Autoradiograms were developed after exposure to x-ray film for 2-4 h at -70°C using a Cronex intensifying screen (DuPont Instruments, Wilmington, DE). The hybridization signal was quantified by densitometry and integration ofthe autoradiographic images using a laser densitometer (model 202; LKB-Instruments, Inc., Gaithersburg, MD). Fig. 1 Conversely, when antral somatostatin was immunoneutralized by the addition of specific antibodies to somatostatin to the incubation medium, gastrin mRNA levels increased by 116±31% (P < 0.01) (Fig. 2) . No changes in the levels of actin or ubiquitin mRNA were detected, indicating specificity ofthe inhibitory effects of somatostatin on gastrin mRNA. In addition, inclusion of the analogue [Leu8,D-Trp22,Tyr28]-somatostatin 28 (10-6 M) in the incubation medium containing somatostatin antiserum inhibited the stimulatory effects of somatostatin immunoneutralization by 36%. When RNA extracts (10 gig) were subjected to Northern blot hybridization analysis, gastrin mRNA migrated as a single species of -620 nucleotides (Fig. 3) . This distinct mRNA species closely matched the predicted size of mature cytoplasmic gastrin mRNA.
Time course experiments were performed aimed at determining the timed effect of antral somatostatin immunoneutralization on gastrin mRNA. Steady-state gastrin mRNA levels were determined after incubation of antral mucosa for 60, 90, 120, and 240 min. An increase in gastrin mRNA level was demonstrated as early as 30 min, and the rate of increase remained nearly constant during the entire 4-h period of observation (data not shown).
Antral mucosal strips were incubated in the presence of increasing concentrations of somatostatin (10-9- control (P < 0.001); and at 10-6 M, 51.9±2.2% of control (P < 0.001) (Fig. 4) presence of N6-2'-O-dibutryladenosine 3':5'-cAMP (DBcAMP; Sigma Chemical Co.), 1o-6 M somatostatin, or both. As shown in Table I , no significant change in gastrin gene transcription could be detected when antral mucosa was incubated with somatostatin alone. However, somatostatin markedly attenuated the 396% increase in the rate of gastrin gene transcription stimulated by DBcAMP (Table I) .
Discussion
Somatostatin has been shown to inhibit gastrin release in a variety of in vivo and in vitro models (2, 14, 15) . The present studies extend this observation by delineating a molecular mechanism for the inhibition of gastrin gene expression by somatostatin. These experiments indicate that in addition to an effect on posttranslational processing of the gastrin peptide (17), somatostatin appears to directly modulate levels of gastrin mRNA. When antral mucosa was incubated in the presence of increasing concentrations of somatostatin, a dose-dependent decrease in gastrin mRNA levels was observed (Fig.  3) . Conversely, in response to immunoneutralization of antral somatostatin by inclusion of specific antibodies in the culture medium, a significant increase in gastrin mRNA levels was detected (Fig. 2) . Previous studies have shown that although somatostatin inhibits growth hormone release by > 90% (33) , it has no effect on the levels of growth hormone mRNA (34, 35) or on growth hormone gene transcription (36) . However, other regulatory peptides have been shown to modulate target cell function at several levels. Insulin is known to enhance the rate of protein synthesis at the translational level by stimulating the rate of peptide chain initiation in heart and skeletal muscle (37, 38) , epididymal fat cells (39) , and cultured fibroblasts (40) . In addition to its effect on translation, insulin also exerts an effect on protein synthesis by modulating levels of mRNA. In the liver insulin increases levels of mRNA of pyruvate kinase (41) , fatty acid synthetase (42), albumin (43) (44) (45) , and glucokinase (46) , and it decreases levels of phosphoenol pyruvate carboxykinase mRNA (47) (48) (49) . Other regulatory peptides have also been shown to affect posttranscriptional processing of mRNA. Prolactin (50) and thyrotropin-releasing hormone (51) have been shown to stabilize casein and prolactin mRNA levels, respectively, in their target tissues. In addition, insulin and estrogen have been shown to inhibit albumin mRNA at transcriptional and posttranscriptional levels in rat hepatoma cells (52) and in the Xenopus liver (53), respectively. Finally, in vitro studies have demonstrated that estrogen reduces the half-life of albumin mRNA from 10 to 3 h (54).
In conclusion, the present studies suggest that antral somatostatin suppresses gastrin cell function at several levels. In addition to its established inhibitory effects on peptide release, somatostatin inhibits steady-state gastrin mRNA levels and has lesser, though significant, effects on gastrin gene transcription. Although these studies suggest a role in the posttranscriptional processing of gastrin mRNA, further studies aimed at direct examination ofgastrin mRNA turnover are necessary to confirm this hypothesis. Future studies using DNA technology and homogeneous populations of cells, rather than intact antral mucosa, should prove invaluable in helping to improve our understanding of the precise mechanisms of action of these gastrointestinal regulatory peptides. 
